FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311732617> ?p ?o ?g. }

• W4311732617 abstract "Abstract Background Declines in the diagnoses of new HIV infections have been reported in geographic areas with higher uptake of PrEP among persons who would benefit from PrEP (PWBP). In the present analysis, we examined the rate of new HIV diagnoses in PWBP prescribed PrEP and those not prescribed PrEP in order to understand the current and potential impact of PrEP in differing geographies. Methods We estimated the rate of new HIV infections among PWBP not prescribed PrEP with a previously described model (Mera et al. 2019) using a combination of published reports and a claims database. HIV rates for individuals prescribed F/TAF or F/TDF (including brand and generic) for PrEP between 10/3/2019 (F/TAF approval) and 6/30/2021 were analyzed from claims data. For those prescribed PrEP, new infections included new HIV diagnosis or addition of HIV treatment within 10 days of PrEP discontinuation. Results Overall, the US HIV diagnosis rate was 61% lower among PWBP prescribed PrEP (1.33 per 100-person year [95%CI: 1.24 – 1.42]) compared to those not prescribed PrEP (3.38 [3.35 – 3.42]). New HIV diagnosis rates by state among PWBP not prescribed PrEP ranged from 0.41 (0.22 – 0.78) in Vermont to 9.96 (9.53 – 11.54) in Mississippi (Figure). The Southern US had the highest regional HIV diagnosis rate among PWBP not prescribed PrEP (4.20 [4.14 - 4.26], Table). HIV diagnosis rates by state among PWBP prescribed PrEP were lower, ranging from 0 to 2.40 (0.05 – 4.75). Eleven states had a greater than 85% lower HIV diagnosis rate among PWBP prescribed PrEP versus those who were not prescribed PrEP, and the greatest differences in diagnosis rates by PrEP prescription status were observed in the Southeastern US states. Figure:The estimated rates of new HIV diagnosis (per 100 person-years) among PWBP who were not prescribed PrEP in 2019 (A) and those prescribed PrEP from 10/3/2019 to 6/30/2021 (B) in the United States.Table:Regional variations of new HIV diagnosis rates among PWBP who were not prescribed PrEP in 2019 and those prescribed PrEP from 10/3/2019 to 6/30/2021 in the United States. Conclusion This study suggests that substantial reductions in HIV diagnosis rates have occurred in people prescribed PrEP in the US. We found large geographic variations in HIV diagnosis rates, with the largest differences by PrEP prescription status occurring in the Southeast US, underscoring the need for PrEP expansion and its potential impact on the HIV epidemic in that region. Furthermore, our findings demonstrate an approach of estimating HIV rates for PWBP prescribed and those not prescribed PrEP, which may be useful in supporting targeted delivery of HIV prevention services in the US. Disclosures Li Tao, MD, PhD, Gilead Sciences: Employee|Gilead Sciences: Employee|Gilead Sciences: Stocks/Bonds|Gilead Sciences: Stocks/Bonds Jen Thorburn, n/a, Gilead Sciences: Grant/Research Support Amanda Kong, DrPH, Gilead Sciences: Grant/Research Support Debra Irwin, PhD, Gilead Sciences: Grant/Research Support Christoph C. Carter, MD, PhD, Gilead Sciences: Employee|Gilead Sciences: Employee|Gilead Sciences: Stocks/Bonds|Gilead Sciences: Stocks/Bonds Moupali Das, MD, Gilead Sciences: Employee|Gilead Sciences: Employee|Gilead Sciences: Stocks/Bonds|Gilead Sciences: Stocks/Bonds Julie Paone, MPH, Gilead Sciences: Grant/Research Support." @default.
• W4311732617 created "2022-12-28" @default.
• W4311732617 creator A5035142704 @default.
• W4311732617 creator A5035417850 @default.
• W4311732617 creator A5044225195 @default.
• W4311732617 creator A5065179641 @default.
• W4311732617 creator A5073519594 @default.
• W4311732617 creator A5076529428 @default.
• W4311732617 creator A5091519967 @default.
• W4311732617 date "2022-12-01" @default.
• W4311732617 modified "2023-10-16" @default.
• W4311732617 title "2088. Real-World Geographic Variations of HIV Diagnosis Rates among Individuals Prescribed and not Prescribed Oral HIV Pre-Exposure Prophylaxis (PrEP) Regimens in the United States" @default.
• W4311732617 doi "https://doi.org/10.1093/ofid/ofac492.1710" @default.
• W4311732617 hasPublicationYear "2022" @default.
• W4311732617 type Work @default.
• W4311732617 citedByCount "0" @default.
• W4311732617 crossrefType "journal-article" @default.
• W4311732617 hasAuthorship W4311732617A5035142704 @default.
• W4311732617 hasAuthorship W4311732617A5035417850 @default.
• W4311732617 hasAuthorship W4311732617A5044225195 @default.
• W4311732617 hasAuthorship W4311732617A5065179641 @default.
• W4311732617 hasAuthorship W4311732617A5073519594 @default.
• W4311732617 hasAuthorship W4311732617A5076529428 @default.
• W4311732617 hasAuthorship W4311732617A5091519967 @default.
• W4311732617 hasBestOaLocation W43117326172 @default.
• W4311732617 hasConcept C126322002 @default.
• W4311732617 hasConcept C142462285 @default.
• W4311732617 hasConcept C144024400 @default.
• W4311732617 hasConcept C149923435 @default.
• W4311732617 hasConcept C187212893 @default.
• W4311732617 hasConcept C2776939746 @default.
• W4311732617 hasConcept C2776983459 @default.
• W4311732617 hasConcept C2778715236 @default.
• W4311732617 hasConcept C2779496540 @default.
• W4311732617 hasConcept C2910823671 @default.
• W4311732617 hasConcept C2993143319 @default.
• W4311732617 hasConcept C3013748606 @default.
• W4311732617 hasConcept C512399662 @default.
• W4311732617 hasConcept C71924100 @default.
• W4311732617 hasConceptScore W4311732617C126322002 @default.
• W4311732617 hasConceptScore W4311732617C142462285 @default.
• W4311732617 hasConceptScore W4311732617C144024400 @default.
• W4311732617 hasConceptScore W4311732617C149923435 @default.
• W4311732617 hasConceptScore W4311732617C187212893 @default.
• W4311732617 hasConceptScore W4311732617C2776939746 @default.
• W4311732617 hasConceptScore W4311732617C2776983459 @default.
• W4311732617 hasConceptScore W4311732617C2778715236 @default.
• W4311732617 hasConceptScore W4311732617C2779496540 @default.
• W4311732617 hasConceptScore W4311732617C2910823671 @default.
• W4311732617 hasConceptScore W4311732617C2993143319 @default.
• W4311732617 hasConceptScore W4311732617C3013748606 @default.
• W4311732617 hasConceptScore W4311732617C512399662 @default.
• W4311732617 hasConceptScore W4311732617C71924100 @default.
• W4311732617 hasIssue "Supplement_2" @default.
• W4311732617 hasLocation W43117326171 @default.
• W4311732617 hasLocation W43117326172 @default.
• W4311732617 hasOpenAccess W4311732617 @default.
• W4311732617 hasPrimaryLocation W43117326171 @default.
• W4311732617 hasRelatedWork W2588903231 @default.
• W4311732617 hasRelatedWork W2605835179 @default.
• W4311732617 hasRelatedWork W2979414777 @default.
• W4311732617 hasRelatedWork W2979609126 @default.
• W4311732617 hasRelatedWork W3080106733 @default.
• W4311732617 hasRelatedWork W3122948194 @default.
• W4311732617 hasRelatedWork W4225961962 @default.
• W4311732617 hasRelatedWork W4308248865 @default.
• W4311732617 hasRelatedWork W4311732617 @default.
• W4311732617 hasRelatedWork W4319728762 @default.
• W4311732617 hasVolume "9" @default.
• W4311732617 isParatext "false" @default.
• W4311732617 isRetracted "false" @default.
• W4311732617 workType "article" @default.